Discovers new radioligands for visualizing GABA transporter 1 in nonhuman primates, suggesting advancements in PET imaging.
The γ-aminobutyric acid (GABA) system regulates neuronal excitability in the central nervous system and is implicated in multiple neuropsychiatric and neurodegenerative disorders. GABA transporter 1 (GAT-1) is a key regulator of synaptic GABA levels but has been difficult to image in vivo due to the lack of blood-brain barrier (BBB)-permeable radioligands for positron emission tomography (PET). Here, we report the design, synthesis, and evaluation of novel tiagabine-based derivatives as brain-penetrant radioligands for GAT-1. Screening of 105 compounds identified four candidates (GATT-31, GATT-34, GATT-39, and GATT-44) with high GAT-1 affinity, appropriate lipophilicity, and low P-glycoprotein efflux liability. These ligands were radiolabeled via copper-mediated ¹⁸F-radiofluorination. PET imaging in nonhuman primates demonstrated good brain uptake of the radioligands. Among them, [¹⁸F]GATT-44 appeared to be the most promising with good metabolic stability and high GAT-1 binding specificity. The discovery of BBB-penetrating radioligands enables, for the first time, in vivo imaging of GAT-1 in the brain.
No takes yet. Share an insight, caveat, or question.
Gu et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: